Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session- NSCLC, metastatic

2887 - IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC


22 Oct 2018


Proffered paper session- NSCLC, metastatic


Cytotoxic Therapy;  Immunotherapy

Tumour Site


Federico Cappuzzo


F. Cappuzzo1, M. McCleod2, M. Hussein3, A. Morabito4, A. Rittmeyer5, H.J. Conter6, H. Kopp7, D. Daniel8, S. McCune9, T. Mekhail10, A. Zer11, N. Reinmuth12, A. Sadiq13, V. Archer14, T. Ochi Lohmann15, L. Wang16, M. Kowanetz17, W. Lin18, A. Sandler19, H. West20

Author affiliations

  • 1 Dipartimento Di Oncologia Medica, Azienda Unità Sanitaria Locale della Romagna, 48100 - Ravenna/IT
  • 2 Sarah Cannon Research Institute, Florida Cancer Specialists, Fort Myers/US
  • 3 Sarah Cannon Research Institute, Florida Cancer Specialists, Leesburg/US
  • 4 Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, Naples/IT
  • 5 Department Of Thoracic Oncology, Lungenfachklinik Immenhausen, Immenhausen/DE
  • 6 Department Of Medicine, William Osler Health System, Ontario/CA
  • 7 Robert Bosch Centrum Für Tumorerkrankungen (rbct), Klinik Schillerhöhe, Stuttgart/DE
  • 8 Medical Oncology, Tennessee Oncology, Chattanooga/US
  • 9 Northwest Georgia Oncology Centers, Marietta Cancer Center, Marietta/US
  • 10 Medical Oncology, Florida Hospital Cancer Institute, Orlando/US
  • 11 Thoracic Oncology Unit, Rabin Medical Center, Tel Aviv University, Tel Aviv/IL
  • 12 Thoracic Oncology, Asklepios Clinics Munich-Gauting, Gauting/DE
  • 13 Fort Wayne Medical, Oncology and Haematology, Fort Wayne/US
  • 14 Pd Oncology, Roche Products Limited, Welwyn Garden City/GB
  • 15 Pd Oncology, F. Hoffmann-La Roche Ltd, Basel/CH
  • 16 Biostatistics, Genentech Inc, South San Francisco/US
  • 17 Oncology Biomarker Development, Genentech Inc, 94080 - South San Francisco/US
  • 18 Clincial Science, Genentech, Inc, South San Francisco/US
  • 19 Clinical Science, Genentech Inc, 94080 - South San Francisco/US
  • 20 Thoracic Oncology Program, Swedish Cancer Institute, Seattle/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2887


Atezo (anti-PD-L1) monotherapy improves overall survival (OS) vs docetaxel in 2L+ NSCLC, regardless of PD-L1 status; phase 3, 1L studies have shown the clinical benefit of atezo plus chemotherapy. IMpower130 (NCT02367781) evaluated atezo + CnP vs CnP in patients (pts) with measurable (RECIST v1.1) stage IV non-squamous NSCLC.


Pts (randomised 2:1) received atezo (1200 mg IV q3w) + CnP (carboplatin: AUC 6 q3w; nab-paclitaxel: 100 mg/m2 IV qw) (Arm A) or CnP (Arm B), for 4 or 6 21-day cycles and maintenance (Arm A: atezo until loss of clinical benefit; Arm B: best supportive care or pemetrexed q3w until disease progression [PD]). Crossover to atezo at PD was initially permitted for Arm B pts. Co-primary endpoints: investigator-assessed PFS and OS (ITT-WT population: EGFR-WT/ALK-negative). Secondary endpoints: OS and PFS (ITT population and by PD-L1 expression), response rate and safety. ITT population could be formally tested for OS/PFS if ITT-WT OS was positive.


723 ITT (679 ITT-WT) pts were enrolled. Statistically significant, clinically meaningful improvements in OS and statistically significant improvements in PFS (ITT and ITT-WT) were observed in Arm A vs Arm B (table). PFS and OS benefit was observed in all PD-L1 subgroups, and consistently across all subgroups, except in pts with liver metastases and EGFR/ALK genomic alterations. In treated pts, 73.2% (Arm A) vs 60.3% (Arm B) had grade 3–4 treatment-related adverse events.

Table. IMpower130 Efficacy Analyses

Arm A
Atezo + CnP

Arm B




Median OS (95% CI)

18.6 mo (16.0–21.2)

13.9 mo (12.0–18.7)

HR (95% CI; P value)

0.79 (0.64–0.98; 0.033)

12-mo OS (95% CI)

63.1% (58.59–67.66)

55.5% (48.89–62.17)

Median PFS (95% CI)

7.0 mo (6.2–7.3)

5.5 mo (4.4–5.9)

HR (95% CI; P value)

0.64 (0.54–0.77; <0.0001)

12-mo PFS (95% CI)

29.1% (24.83–33.44)

14.1% (9.37–18.76)



Confirmed ORR (investigator assessed) (95% CI)

49.2% (44.49–53.96)

31.9% (25.84–38.36)



Median DOR (95% CI)

8.4 mo (6.9–11.8)

6.1 mo (5.5–7.9)

PD-L1 higha



Median OS (95% CI)

17.4 mo (14.78–NA)

16.9 mo (10.94–NA)

HR (95% CI)

0.84 (0.51–1.39)

Median PFS (95% CI)

6.4 mo (5.49–9.76)

4.6 mo (3.22–7)

HR (95% CI)

0.51 (0.34–0.77)

PD-L1 lowa



Median OS (95% CI)

23.7 mo (18.63–NA)

15.9 mo (12.32–25.63)

HR (95% CI)

0.70 (0.45–1.08)

Median PFS (95% CI)

8.3 mo (7.16–10.35)

6.0 mo (5.29–6.93)

HR (95% CI)

0.61 (0.43–0.85)

PD-L1 negativea



Median OS (95% CI)

15.2 mo (12.88–19.15)

12.0 mo (8.97–17.71)

HR (95% CI)

0.81 (0.61–1.08)

Median PFS (95% CI)

6.2 mo (5.52–7.16)

4.7 mo (4.11–5.72)

HR (95% CI)

0.72 (0.56–0.91)




Median OS (95% CI)

18.1 mo (15.3–20.8)

13.9 mo (12.0–18.2)

HR (95% CI; P value)

0.80 (0.65–0.99; 0.039)

Median PFS (95% CI)

7.0 mo (6.3–7.3)

5.6 mo (4.5–5.9)

HR (95% CI; P value)

0.65 (0.54–0.77; <0.0001)

a PD-L1 high (TC3 or IC3): Patients with PD-L1 expression in ≥50% of tumour cells or ≥10% of tumour-infiltrating immune cells; PD-L1 low (TC1/2 or IC1/2): Patients with PD-L1 expression in ≥1% and <50% of tumour cells or ≥1% and <10% of tumour-infiltrating immune cells; and PD-L1 negative (TC0 and IC0): Patients with PD-L1 expression in <1% of tumour cells and <1% of tumour-infiltrating immune cells. Data cut-off: 15 March 2018. Minimum follow up: 13 months. NCT02367781.

DOR, duration of response; HR, hazard ratio; IC, immune cells; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TC, tumour cells.


Overall, IMpower130 showed statistically significant, clinically meaningful improvements in OS and statistically significant improvements in PFS with atezo + CnP, vs CnP, in 1L, stage IV non-squamous NSCLC, in this predominantly ITT-WT population. No new safety signals were identified.

Clinical trial identification

NCT02367781 (20 February 2015).

Editorial Acknowledgement

Support for third-party writing assistance for this abstract, furnished by Islay Steele, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.